|MDACC Study No:||2010-0842 (clinicaltrials.gov NCT No: NCT01434303)|
|Title:||Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and |
Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer in
Whom Trastuzumab Has Failed
|Principal Investigator:||Naoto Ueno|
|Treatment Agent:||Entinostat; Lapatinib; Trastuzumab|
|Study Description:||This goal of this clinical research study is to find the highest tolerable dose |
of entinostat and lapatinib that can be given in combination to patients with
advanced or metastatic breast cancer. The effectiveness and safety of this
dose combination will be studied. Researchers will also study the safety of
the other dose combinations.
Entinostat in an investigational drug and is not FDA approved or commercially
available. It is currently being used for research purposes only. Lapatinib is
approved by the FDA for certain kinds of breast cancer. The combination of
these drugs is investigational.